P553: A PHASE 2, OPEN-LABEL, MULTIARM, MULTICENTER STUDY TO EVALUATE MAGROLIMAB COMBINED WITH ANTILEUKEMIA THERAPIES FOR FIRST-LINE, RELAPSED/REFRACTORY, OR MAINTENANCE TREATMENT O... by P. Vyas, N. G. Daver, M. P. Chao, G. Xing, C. Renard, G. Ramsingh, A. H. Wei, D. A. Sallman

Get full text

P551: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53-MUTANT ACU... by N. G. Daver, P. Vyas, M. P. Chao, G. Xing, C. Renard, G. Ramsingh, D. A. Sallman, A. H. Wei

Get full text

PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS by N. Rajakumaraswamy, M. Gandhi, A. H. Wei, D. A. Sallman, N. G. Daver, S. Mo, S. Iqbal, M. Chen, Y. Wang, P. Vyas

Get full text

P774: CLINICAL OUTCOMES ASSOCIATED WITH AZACITIDINE MONOTHERAPY FOR TREATMENT-NAIVE PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A SYSTEMATIC LITERATURE REVIEW AND... by K. Hasegawa, A. H. Wei, G. Garcia-Manero, N. G. Daver, N. Rajakumaraswamy, S. Iqbal, R. J. Chan, H. Hu, P. Tse, J. Yan, M. J. Zoratti, F. Xie, D. A. Sallman

Get full text

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML O... by G. Garcia-Manero, E. S. Winer, D. J. DeAngelo, S. Tarantolo, D. A. Sallman, J. Dugan, S. Groepper, A. Giagounidis, K. Götze, K. H. Metzeler, C.-C. Li, L. Zhou, E. Martinez, M. Lane, R. von Roemeling, M. Bohme, A. S. Kubasch, A. Verma, U. Platzbecker

Get full text

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS by D. A. Sallman, M. M. Al Malki, A. S. Asch, E. S. Wang, J. G. Jurcic, T. J. Bradley, I. W. Flinn, D. A. Pollyea, S. N. Kambhampati, T. N. Tanaka, J. F. Zeidner, G. Garcia-Manero, D. Jeyakumar, L. Gu, A. Tan, M. Chao, C. O’Hear, I. Lal, P. Vyas, N. Daver

Get full text

P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS) by C. D. DiNardo, J. M. Foran, J. M. Watts, E. M. Stein, S. de Botton, A. T. Fathi, G. T. Prince, R. M. Stone, P. A. Patel, G. J. Roboz, M. L. Arellano, H. P. Erba, A. Pigneux, P. Baratam, R. K. Stuart, X. Thomas, I. R. Lemieux, X. Bai, S. M. Kapsalis, G. Garcia-Manero, D. A. Sallman

Get full text

P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYEL... by A. M. Zeidan, A. Al-Kali, U. Borate, T. Cluzeau, A. E. DeZern, J. Esteve, A. Giagounidis, K. Kobata, R. Lyons, U. Platzbecker, D. A. Sallman, V. Santini, G. F. Sanz, M. A. Sekeres, A. H. Wei, Z. Xiao, M. Van Hoef, C. Nourry-Boulot, I. Sadek, F. Ma, A. Iordan, J. Sabo, G. Garcia-Manero

Get full text